Publication | Closed Access

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study

Second-line TreatmentOncologyCancer ManagementPoor PrognosisCancer TreatmentMedicineRadiation OncologyLung CancerErlotinib Versus Chemotherapy